anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The tissue healing and regeneration involves the joint and organised activity of different types of cells and specific growth factors. The wounds that are not suitably healed generally lead to ulceration, necrosis and amputation of the limb, this representing one of the most sever consequences of diabetes, which due to its high morbidity index represents one of the most important problems on health in Mexico. Nowadays, there is no alternative for accelerating and promoting the wound healing processes, with special interest in diabetic patients. Due to the aforementioned aspects, a pharmaceutical composition was developed from a mixture of a platelet lysate and hydrogel. The association of both components has an important healing activity over stratified epithelia that have been injured by a mechanical or chemical effect in healthy individuals or those who suffer from diabetes mellitus. The invention provides the only alternative to have, in a simultaneous manner, growth factors that p romote the cell division and a tissue regeneration associated with a vehicle formed by a hydrosoluble polymer Pluronic F-127, which provides unique advantages upon allowing the addition of analgesics, antibiotics or anti-inflammatory agents, also facilitating the preservation, topical application and protection thereof against the thermal denaturalisation.
Fentanyl (1mg/kg i.v.) will be administered before general anaesthesia (GA). GA will be maintained with inhalation anaesthetics (isoflurane) at a minimum alveolar concentration of 0.7-1.3.
The invention relates to the field of microorganisms, and particularly provides bifidobacterium longum TC01, application thereof and a product using the same. The Bifidobacterium longum TC01 provided by the invention has a preservation number of CGMCC No. 12728. The Bifidobacterium longum TC01 can be isolated from healthy human intestinal tract, and has good safety and no side effects and metabolic burden. The Bifidobacterium longum TC01 has good acid and bile salt resistance, and can reach gastrointestinal tract and exert its beneficial function with less activity loss. The Bifidobacterium longum TC01 has broad-spectrum resistance, and can significantly inhibit Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, Shigella or Streptococcus pneumoniae. The bifidobacterium longum TC01 is taken as a beneficial bacterium and is prepared into a corresponding product which can be practically applied, and the application potential in related fields is very large.
Alendronate Sodium Oral Solution is a bisphosphonate that acts as a specific inhibitor of osteoclast-mediated bone resorption. Bisphosphonates are synthetic analogs of pyrophosphate that bind to the hydroxyapatite found in bone.

Alendronate sodium is chemically described as (4-amino-1-hydroxybutylidene) bisphosphonic acid monosodium salt trihydrate.

The empirical formula of alendronate sodium is C4H12NNaO7P2∙3H2O and its formula weight is 325.12. The structural formula is:

Alendronate sodium USP is a white powder. It is soluble in water, very slightly soluble in alcohol, and practically insoluble in chloroform.

Each bottle of the oral solution contains 91.35 mg of alendronate monosodium salt trihydrate, which is the molar equivalent to 70 mg of free acid. Each bottle also contains the following inactive ingredients: citric acid (anhydrous), methylparaben, propylparaben, purified water, raspberry blend, saccharin sodium and sodium citrate.
The present disclosure provides isolated monoclonal antibodies that specifically bind to CD70 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human CD70. In certain embodiments, the antibodies are capable of being internalized into CD70-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD70, as well as methods for treating cancers, such as renal cancer and lymphomas, using an anti-CD7Q antibody of this disclosure.
The invention relates to a traditional Chinese medicine composition for treating bovine mastitis. The composition is prepared from radix bupleuri, cowherb seeds, selfheal, oysters, safflower carthamus, ligusticum wallichii, radix paeoniae rubra and pangolin scale. The traditional Chinese medicine composition can be powder. The preparation method comprises the following steps: (1) weighing the traditional Chinese medicinal materials according to the prescribed amount; (2) grinding the traditional Chinese medicinal materials, and screening through a 40-80-mesh screen; (3) mixing the traditional Chinese medicinal materials for 5-15 minutes to obtain traditional Chinese medicinal powder; and (4) subpackaging the traditional Chinese medicinal powder according to the mode of filling each bag with 100-200g of the traditional Chinese medicinal powder to obtain a finished product. The formula of the traditional Chinese medicine composition has the effects of clearing heat, purging internal heat, eliminating carbuncles and swelling, promoting blood circulation to remove stasis and promoting qi circulation to relieve pain. The traditional Chinese medicine composition can be used for effectively treating bovine mastitis, and has a cure rate of 85.7 percent.
The randomly selected group of subjects who will receive the intervention. The radiologist performing the transrectal prostate biopsy on these subjects will have a gauze soaked with Povidone-iodine over his/her index finger, and will insert this into the rectum. This gauze will be wiped back and forth across the prostate with the finger at least five times from one lateral margin to the other. This will be allowed to dry for 2 minutes before proceeding with the biopsy.
Methods and systems for performing 3-D LIDAR measurements of objects simultaneously illuminated by two or more beams of light in the far field are described herein. A 3-D LIDAR based measurement device simultaneously emits at least two beams of light into a three dimensional environment from different locations. A portion of the three dimensional environment is simultaneously illuminated by the two or more light beams at a distance of at least five meters from the LIDAR device. However, the two or more light beams do not overlap at a distance less than five meters from the LIDAR device. The beams of light are slightly divergent, having highest intensity at the device and steadily lower intensity further away. By overlapping illumination beams in the far field, but not near the LIDAR device, overall intensity is maintained at moderate levels throughout the field of view of the LIDAR device.
Desipramine was started at a dose of 25 mg per day. The dose was gradually increased over 2 weeks to 200 mg per day.
PURPOSE:To shorten a preparation time by dispensing with work partially eliminating the base bottom surface of an artificial tooth and to prevent the damage of the outer shape of the artificial tooth by providing a cavity having a specific recessed shape and the width and length of a neck part to a region from a base bottom part to a lingual leading end part. CONSTITUTION:The max. cavity depth 3 of an artificial tooth for an front tooth part is set to 0.5-5.0mm considering the size of a retaining device or connector of every kind. When the max. cavity depth is below 0.5mm, space including the retaining device or connector of every kind is insufficient and the bottom surface of the artificial tooth must be further eliminated and a dental technical operation time becomes long or the outer shape of the artificial tooth is often damaged. When the max. cavity depth exceeds 0.5mm, a ligulal diameter becomes necessarily large and a feeling of physical disorder at the time of mounting in the oral cavity increases. Further, the value of {(cavity long diameter 2)/(total long diameter 5)}X100 is set to 10-100%. The mix. thickness 4 of a neck part is set to 0.1-5.0mm. By this method, strength or abrasion resistance is also enhanced.
Participants will initially apply ruxolitinib 1.5%mg cream as a monotherapy. At week 12, those who have \< 25% improvement in total body Vitiligo Area Scoring Index (T-VASI25) will have NB-UVB phototherapy added to their ruxolitinib 1.5% cream BID regimen. NB-UVB will be given 3 times per week starting at Week 12 through Week 48 (36 weeks). For participants who receive combination therapy, NB-UVB machines will be supplied by the sponsor for at home use during the study.
The radiobiology of tumor reirradiation is poorly understood. It pertains to tumors and their sensitivity at the time of relapse, encompassing primary tumors, metastases, or secondary cancers developed in or proximal to previously irradiated tissues. The ability to control the pathology depends, in part, on understanding this sensitivity. To date, literature data remains limited regarding changes in the radiosensitivity of tissues after initial irradiation, and most proposals are based on conjecture. The response of healthy tissues at the site of irradiation raises concerns about radio-induced complications. Cumulative dose is likely a major factor in this risk, thus using equivalent dose calculations might help reduce the risk of complications. However, the correlation between mathematical equivalence formulas and clinical effects of radiobiological origin is weak, and the lack of knowledge of the alpha/beta (α/β) ratio of healthy tissues remains an obstacle to the extensive use of these formulas. However, tissues exposed to recovery dose may have a tolerance to irradiation much higher than assumed, thus further biological work remains to be developed. Also, the functionality of previously irradiated tissues could be useful in selecting the most suitable irradiation beams. Finally, research on the genomics of irradiated healthy tissues could improve the prediction of side effects and personalize radiotherapy.
Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6. While this pathway may be blocked by a variety of drugs (e.g., certain cardiovascular drugs and antidepressants), such blockade has not yet been shown to be of clinical significance with this agent. However, clinicians should be aware of this possible interaction.

Neuromuscular Blocking Agents: Oxycodone, as well as other opioid analgesics, may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.

CNS Depressants: Patients receiving narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics or other CNS depressants (including alcohol) concomitantly with oxycodone hydrochloride tablets may exhibit an additive CNS depression. Interactive effects resulting in respiratory depression, hypotension, profound sedation, or coma may result if these drugs are taken in combination with the usual dosage of oxycodone hydrochloride tablets. When such combined therapy is contemplated, the dose of one or both agents should be reduced.

Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) should be administered with caution to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride tablets. In this situation, mixed agonist/antagonist analgesics may reduce the analgesic effect of oxycodone hydrochloride tablets and/or may precipitate withdrawal symptoms in these patients.

Monoamine Oxidase Inhibitors (MAOIs): MAOIs have been reported to intensify the effects of at least one opioid drug causing anxiety, confusion and significant depression of respiration or coma. The use of oxycodone hydrochloride tablets is not recommended for patients taking MAOIs or within 14 days of stopping such treatment.
Group of participants with a main diagnosis of social anxiety disorder (n=26) subjected to individual online delivered 12 sessions ACT psychotherapy. Participants pertaining to this group will be assessed at 4 different time points (pre- and post-treatment and at a 3- and 6- month follow-up).
In response to Mazaheri et al.'s critique, we revisited our study (Valentini et al., 2022) on the relationship between peak alpha frequency (PAF) and pain. Their commentary prompted us to reassess our data to address the independence between slow and slowing alpha brain oscillations, as well as the predictivity of slow alpha oscillations in pain perception. Bayesian correlation analyses revealed mixed support for independence. Investigating predictivity, we found inconsistent associations between pre-PAF and unpleasantness ratings. We critically reflected on methodological and theoretical issues on the path to PAF validation as a pain biomarker. We emphasized the need for diversified methodology and analytical approaches as well as robust findings across research groups.
In addition to the standard rehabilitation care in the concussion clinic, the intervention group will have a daily 10-minutes paced breathing home-exercise program. The paced breathing exercise including inhale for 4-second and exhale for 6-seconds, for a total of 6 breaths per minute.
Develop methodologies to promote recovery of reaching and grasping movements. To accomplish this goal, the investigators will combine TESS applied in a closed-loop manner with massed practice upper-limb training. Participants will be assigned to one of three groups in a randomized order for a controlled design: \[1) Closed-loop TESS applied during grasping + training, 2) Closed-loop TESS applied during reaching + training, and 3) Closed-loop TESS applied during grasping \& reaching + training.\] TESS for 20-min will be followed by 60 min of massed practice exercise training (total=20 sessions).
The study aimed to investigate the association of frailty with diverse geriatric health characteristics and how the latter might contribute to the former. Cross-sectional data of 140 women aged over 75 years were analyzed. Fried's definition of physical frailty, psychological, sex hormones, disability and physical fitness outcomes were examined. Prevalence of frailty was 40%. Frail women had lower scores in cognitive and physical fitness, and high scores for depression and comorbidities. Significant correlations emerged between frailty and disability, fear of falling, aerobic resistance and cognition showed that only aerobic resistance and cognition. A trend towards lower systolic blood pressure in the frail group may reflect being less physically active and/or having more systemic comorbidity. Using simple functional fitness and cognitive measures rather than using less reliable self-report assessments can better identify those with physical frailty.
Diabetic kidney disease (DKD) is one of the most serious complications of diabetes and has become the leading cause of end-stage kidney disease, causing serious health damage and a huge economic burden. Tubulointerstitial fibrosis play important role in the development of DKD. Itaconate, a macrophage-specific metabolite, has been reported to have anti-oxidant, anti-inflammatory effects. However, it is unknown whether it perform anti-fibrotic effect in renal tubular epithelial cells. In this current study, we observed that in human renal tubular epithelial cells (HK2), high glucose induced an increase in transforming growth factor β (TGF-β) production, and upregulated the expressions of fibronectin and collagen I through the TGF-β receptor as verified by administration of TGF-β receptor blocker LY2109761. Treatment with 4-octyl itaconate (4-OI), a derivant of itaconic acid, reduced the TGF-β production induced by high glucose and inhibited the pro-fibrotic effect of TGF-β in a dose-dependent manner. In addition, we found that 4-OI exerted its anti-fibrotic effect by inhibiting the excessive production of ROS induced by high glucose and TGF-β. In summary, 4-OI could ameliorate high glucose-induced pro-fibrotic effect in HK2 cell, and blocking the expression of TGF-β and reducing the excessive ROS production may be involved in its anti-fibrotic effect.
FIELD: medicine, applicable in oncology and dermatology. SUBSTANCE: the method for photodynamic therapy of pathologic surface formations consists in sensitization of the surface of the pathologic section by application of an applicator containing pentaaminolevulinic acid, and irradiation of the sensitized section by therapeutic optical radiation in the spectral band within 625 to 700 nm, the applicator is made transparent in the spectral band at least within 625 to 700 nm, and irradiation is accomplished through the applicator. The applicator has a base of bioinert material and sensitized layer. The layer comprises a carrier and pentaaminolevulinic acid dissolved or dispersed in the carrier. The base is made in the form of a film of bioinert polymer that is transparent in the spectral band at least within 625 to 700 nm. Used as a carrier is a film layer of biocompatible hydrophilic copolymers of N-vinylpyrrolidone with derivatives of acrylic acid representing terpolymers of N-vinylpyrrolidone, acrylic acid amide and acrylic acid ethyl ether. The relationship of monometric members respectively (20-35): (3-60):(20-30) percent by mass and molecular mass within 20000 to 1 mln daltons. EFFECT: enhanced efficiency of photodynamic therapy of pathalogic surface sections due to optimization of sensitization processes and irradiation of the pathalogic section as well as reduced consumption of pentaaminolevulinic acid. 5 cl
PURPOSE: To obtain a suppressant for carcinogenesis, containing a crude drug selected from Rhei Rhizoma, Gardenia Fructus, Coptidis Rhizome and Scutellariae Radix as an active ingredient, having great effects especially on prevention of onset of carcinoma of the colon and expectable great effects by administering to a patient, etc., suffering from the familial carcinoma of the colon. CONSTITUTION: This suppressant for carcinogenesis contains a crude drug selected from Rhei Rhizoma, Gardenia Fructus, Coptidis Rhizoma and Scutellariae Radix as an active ingredient. A Chinese medicinal formulation prepared by combining the crude drugs is preferably used as the crude drug. For example, SANOSHASHIN-TO (containing the Rhei Rhizoma, the Scutellariae Radix, the Coptidis Rhizoma, etc.), ORENGEDOKU-TO (containing the Coptidis Rhizoma, Phellondendri Cortex, the Scutellariae Radix, the Gardenia Fructus, etc.), TOKAKUJYOKI-TO (containing Pruni Persicae Semen, Cinnamomi Cortex, the Rhei Rhizoma, Glycyrrhizae Radix, etc.), SAIKOKARYUKOTSUBOREI-TO (containing Bupleuri Radix, Pinnelliae Tuber, Hoelen, Cinnamomi Cortex, the Scutellariae Radix, Zingiberis Rhizoma, the Rhei Rhizoma, etc.) and DAISAIKO-TO (Bupleuri Radix, Pinnelliae Tuber, Zingiberis Rhizoma, the Scutellariae Radix,  the Rhei Rhizoma, etc.) are cited as the Chinese medicinal formu1ation. The objective medicine can mainly and perorally be administered. The daily dose thereof for an adult is preferably 0.5-30g exprgssed in terms of the Rhei Rhizoma used alone, 0.5-50g expressed in terms of the Gardenia Fructus used alone, 0.25-45g expressed in terms of the Coptidis Rhizoma used alone and 1-50g expressed in terms of the Scutellariae Radix used alone. When the Chinese medicinal formulation, e.g. the SANOSHASHIN-TO is used, the dose thereof may be 0.1-50g.
In the Manual manipulation group, the thrust was applied in the right side of C3/C4 with neutral flexion/extension, ipsilateral side bending and contralateral rotation. Then, a low amplitude, high velocity thrust in rotation was delivered.
TNKS is a new target for the treatment of lung adenocarcinoma, the synergistic effects of the TCM compound Xiaoyan decoction and the TNKS inhibitor E7449 in the intervention on TNKS were investigated, and the possible underlying mechanisms involved were clarified. Immunohistochemistry was used to analyse TNKS expression in tumour tissues. The impact of targeting TNKS on cell growth, invasion, apoptosis, key genes and signalling pathways was investigated in tumour cells by Western blotting, rescue experiments, colony formation assays, flow cytometry and label-free experiments. Tumour xenografts with A549 cells were then transplanted for in vivo study. We found that TNKS high expression was closely related to the advanced tumour stage and tumour size in lung adenocarcinom. After TNKS was knocked down in vitro, the growth, proliferation, migration and invasion were markedly reduced in A549 and H1975 cells. We subsequently applied the Xiaoyan decoction and TNKS inhibitors to intervene in lung adenocarcinoma. Xiaoyan decoction and E7449 suppressed TNKS expression and inhibited adenocarcinoma cell proliferation, migration, invasion and apoptosis in vitro. Proteomic analysis revealed that E7449 treatment may be most closely associated with the classic Wnt/β-catenin pathway, whereas Xiaoyan decoction treatment may be related to the WNT/PLAN pathway. Xenograft studies confirmed that E7449 or Xiaoyan decoction inhibited lung tumour growth in vivo and attenuated the Wnt signalling pathway in adenocarcinoma. These findings suggest that TNKS is a novel therapeutic target. TCM preparations and small molecule inhibitors are expected to constitute an effective combination strategy.
Endometrial (uterine) cancer affects over 40,000 women each year in the United States. At this time there are no medications to prevent endometrial cancer. Women who are heavy are at increased risk of this cancer. Progestins have been used to treat endometrial hyperplasia and cancer in women who wanted to retain their fertility or who were not surgical candidates. Oral progestins are associated with side effects such as weight gain, mood changes, headaches, and acne. A device called Mirena has a type of progesterone in it. Because it is placed directly in the uterus it can give a powerful amount of progestin with less side effects. In this project, we will enroll 44 women who are aged 40-50 and who have a body mass index (BMI) greater than 40. (BMI is a measure of obesity. Normal is less than 25.) They will be randomized to either observation or treatment. The women in the treatment group will have a levonorgestrel intrauterine system (Mirena, LNG-IUS) placed for one year. All of the women will have endometrial biopsies and blood work at the beginning and end of the study. All of the women will have an ultrasound at the beginning of the study. The information will then be used to assess whether or not the LNG-IUS will be an effective prevention agent. The women will be contacted once a year for 5 years to see if they have had endometrial hyperplasia or cancer. A special lab study called microarray will be used to see what genes are turned on or off in the uterine lining.
The present invention discloses diarylhydantoin compounds and methods for synthesizing them and using them in the treatment of a hyperproliferative disorder such as hormone refractory prostate cancer. The invention includes a compound having the formula (see formula) where R1 and R2 together can include eight or fewer carbon atoms and can be selected from the group consisting of alkyl, substituted alkyl, and, together with the carbon to which they are linked, a cycloalkyl or substituted cycloalkyl group. R3 can be hydrogen, cyano, formyl, (see formula) R4 can be hydrogen, F, CI, Br, or I. R11 and R12 can be the same or different and are hydrogen or methyl. R13 can be hydrogen or -NR14R15. R14 and R15 can be the same or different and are hydrogen or methyl. Therefore 1-[(4-cyano-3-trifluoromethylphenyl)]-3-(4-substituted propylphenyI)-5-oxo-2-thioxoimidazolidine derivatives are disclosed and a process to make these derivatives, pharmaceutical compositions, and the medical use of such derivatives for the treatment of proliferative diseases such as cancer.